Repligen (RGEN) Non-Current Debt (2017 - 2026)

Repligen (RGEN) posted quarterly Non-Current Debt of $551.0 million for Q2 2026, up 0.82% quarter-over-quarter from $546.6 million in Q1 2026.

Repligen (RGEN) Non-Current Debt (2017 - 2026) Analysis & Trends

Repligen (RGEN) has reported Non-Current Debt for 5 consecutive years, with $551.0 million the latest figure, recorded in Q2 2026.

In Q2 2026, Non-Current Debt changed N/A year-over-year to $551.0 million; the TTM figure through Jun 2026 stood at $551.0 million (changed N/A YoY), while the FY2025 annual figure was $542.2 million, up 3.17% from the prior year.
Non-Current Debt grew to $551.0 million in Q2 2026 per RGEN's latest filing, from $546.6 million in the prior quarter.
Across five years, Non-Current Debt topped out at $551.0 million in Q2 2026 and bottomed at $525.6 million in Q4 2024.
Historically, Non-Current Debt has averaged $540.7 million across 3 years, with a median of $542.2 million in 2025.
On a YoY basis, Non-Current Debt climbed as much as 3.17% in 2025 and fell as far as 3.17% in 2025.
Repligen's Non-Current Debt stood at $525.6 million in 2024, then climbed by 3.17% to $542.2 million in 2025, then climbed by 1.63% to $551.0 million in 2026.
Business Quant data shows RGEN's Non-Current Debt at $551.0 million in Q2 2026, $546.6 million in Q1 2026, and $542.2 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Intuitive Surgical	134.13 Bn	128.91 Bn	1.96 Bn	-
2	Becton Dickinson	52.76 Bn	51.90 Bn	2.32 Bn	13.51 Bn
3	Alcon	35.81 Bn	34.46 Bn	1.68 Bn	4.15 Bn
4	Resmed	33.72 Bn	32.25 Bn	861.22 Mn	399.42 Mn
5	Medline	29.38 Bn	26.70 Bn	2.22 Bn	12.55 Bn
6	West Pharmaceutical Services	25.00 Bn	24.57 Bn	329.20 Mn	202.90 Mn
7	Solventum	15.46 Bn	15.06 Bn	1.29 Bn	4.57 Bn
8	Cooper Companies	14.88 Bn	14.74 Bn	735.40 Mn	1.86 Bn
9	Baxter International	13.58 Bn	11.43 Bn	1.03 Bn	8.62 Bn
10	Repligen	10.25 Bn	9.24 Bn	110.04 Mn	551.05 Mn

Download Data